 Connection
Daniel LaBarbera to Female
This is a "connection" page, showing publications Daniel LaBarbera has written about Female.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.175 |
|
|
|
-
Esquer H, Zhou Q, LaBarbera DV. Targeted Inhibition of CHD1L by OTI-611 Reprograms Chemotherapy and Targeted Therapy-Induced Cell Cycle Arrest and Suppresses Proliferation to Produce Synergistic Antitumor Effects in Breast and Colorectal Cancer. Cells. 2025 02 20; 14(5).
Score: 0.032
-
Sala R, Esquer H, Kellett T, Clune S, Awolade P, Pike LA, Zhou Q, Messersmith WA, LaBarbera DV. CHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models. Int J Mol Sci. 2024 Dec 07; 25(23).
Score: 0.032
-
Sala R, Esquer H, Kellett T, Kearns JT, Awolade P, Zhou Q, LaBarbera DV. CHD1L Regulates Cell Survival in Breast Cancer and Its Inhibition by OTI-611 Impedes the DNA Damage Response and Induces PARthanatos. Int J Mol Sci. 2024 Aug 06; 25(16).
Score: 0.031
-
Abbott JM, Zhou Q, Esquer H, Pike L, Broneske TP, Rinaldetti S, Abraham AD, Ramirez DA, Lunghofer PJ, Pitts TM, Regan DP, Tan AC, Gustafson DL, Messersmith WA, LaBarbera DV. First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. Mol Cancer Ther. 2020 08; 19(8):1598-1612.
Score: 0.023
-
Yoo BH, Axlund SD, Kabos P, Reid BG, Schaack J, Sartorius CA, LaBarbera DV. A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer. J Biomol Screen. 2012 Oct; 17(9):1211-20.
Score: 0.013
-
Li Q, Chen C, Kapadia A, Zhou Q, Harper MK, Schaack J, LaBarbera DV. 3D models of epithelial-mesenchymal transition in breast cancer metastasis: high-throughput screening assay development, validation, and pilot screen. J Biomol Screen. 2011 Feb; 16(2):141-54.
Score: 0.012
-
Klosowski ML, Cronise KE, Palmer EP, McAuliffe K, Stratton C, Sparks K, Malmstrom KT, Knott-Byars G, Zhou Q, Esquer H, LaBarbera DV, Regan DP. Breast cancer cell coculture induces normal lung fibroblast transition to CAFs, promoting tumor cell dormancy and therapy resistance. Proc Natl Acad Sci U S A. 2025 Nov 25; 122(47):e2423894122.
Score: 0.008
-
Hicks HM, McKenna LR, Espinoza VL, Pozdeyev N, Pike LA, Sams SB, LaBarbera D, Reigan P, Raeburn CD, E Schweppe R. Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. Mol Carcinog. 2021 03; 60(3):201-212.
Score: 0.006
-
Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera DV, Landa I, Knauf JA, Fagin JA, Haugen BR. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Mol Cancer Res. 2019 05; 17(5):1036-1048.
Score: 0.005
-
Fettig LM, McGinn O, Finlay-Schultz J, LaBarbera DV, Nordeen SK, Sartorius CA. Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells. Oncogene. 2017 11 02; 36(44):6074-6084.
Score: 0.005
-
Medellin DC, Zhou Q, Scott R, Hill RM, Frail SK, Dasari R, Ontiveros SJ, Pelly SC, van Otterlo WA, Betancourt T, Shuster CB, Hamel E, Bai R, LaBarbera DV, Rogelj S, Frolova LV, Kornienko A. Novel Microtubule-Targeting 7-Deazahypoxanthines Derived from Marine Alkaloid Rigidins with Potent in Vitro and in Vivo Anticancer Activities. J Med Chem. 2016 Jan 14; 59(1):480-5.
Score: 0.004
-
Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, Labarbera DV, Sartorius CA. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties. Horm Cancer. 2013 Feb; 4(1):36-49.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|